Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2007-04-12 20:20:42 UTC |
---|
Update Date | 2021-09-14 15:40:23 UTC |
---|
HMDB ID | HMDB0006013 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 7a,17-dimethyl-5b-Androstane-3a,17b-diol |
---|
Description | 7a,17-dimethyl-5b-Androstane-3a,17b-diol is a urinary metabolite of the anabolic androgenic steroid (AAS) bolasterone. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. The use of anabolic steroids was banned by the International Olympic Committee for the first time at the Olympic Games in Montreal in 1976. Since that time the misuse of anabolic steroids by athletes has been controlled by analysis of urine of the excreted steroids or their metabolites, or both. (PMID: 10932808 , 14976846 , 15042372 , 15231229 , 16195040 , 16292586 , 1663826 , 16799097 , 16888758 , 16923823 , 17667636 , 17723876 , 17723877 , 2079979 , 3308301 , 8456050 , 8674183 , 8725393 , 9216475 ). |
---|
Structure | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)C[C@]2([H])C[C@H](O)CC[C@]12C InChI=1S/C21H36O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h13-18,22-23H,5-12H2,1-4H3/t13-,14-,15-,16+,17+,18-,19+,20+,21+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(3a,5b,7a,17b)-7,17-Dimethyl-androstane-3,17-diol | HMDB | 7a,17a-Dimethyl-5b-androstane-3a,17b-diol | HMDB |
|
---|
Chemical Formula | C21H36O2 |
---|
Average Molecular Weight | 320.5093 |
---|
Monoisotopic Molecular Weight | 320.271530396 |
---|
IUPAC Name | (1S,2S,5R,7R,9R,10R,11S,14S,15S)-2,9,14,15-tetramethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecane-5,14-diol |
---|
Traditional Name | (1S,2S,5R,7R,9R,10R,11S,14S,15S)-2,9,14,15-tetramethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecane-5,14-diol |
---|
CAS Registry Number | 13611-10-4 |
---|
SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)C[C@]2([H])C[C@H](O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C21H36O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h13-18,22-23H,5-12H2,1-4H3/t13-,14-,15-,16+,17+,18-,19+,20+,21+/m1/s1 |
---|
InChI Key | ZWQUPIDNCOVROC-HEEAJRSSSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 17-hydroxysteroid
- 3-alpha-hydroxysteroid
- Hydroxysteroid
- 3-hydroxysteroid
- Tertiary alcohol
- Cyclic alcohol
- Secondary alcohol
- Organic oxygen compound
- Hydrocarbon derivative
- Organooxygen compound
- Alcohol
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
7a,17-dimethyl-5b-Androstane-3a,17b-diol,1TMS,isomer #1 | C[C@@H]1C[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C)[C@@H]21 | 2645.1 | Semi standard non polar | 33892256 | 7a,17-dimethyl-5b-Androstane-3a,17b-diol,1TMS,isomer #2 | C[C@@H]1C[C@@H]2C[C@H](O[Si](C)(C)C)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O)[C@@H]21 | 2616.7 | Semi standard non polar | 33892256 | 7a,17-dimethyl-5b-Androstane-3a,17b-diol,2TMS,isomer #1 | C[C@@H]1C[C@@H]2C[C@H](O[Si](C)(C)C)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C)[C@@H]21 | 2653.9 | Semi standard non polar | 33892256 | 7a,17-dimethyl-5b-Androstane-3a,17b-diol,1TBDMS,isomer #1 | C[C@@H]1C[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C(C)(C)C)[C@@H]21 | 2912.6 | Semi standard non polar | 33892256 | 7a,17-dimethyl-5b-Androstane-3a,17b-diol,1TBDMS,isomer #2 | C[C@@H]1C[C@@H]2C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O)[C@@H]21 | 2886.3 | Semi standard non polar | 33892256 | 7a,17-dimethyl-5b-Androstane-3a,17b-diol,2TBDMS,isomer #1 | C[C@@H]1C[C@@H]2C[C@H](O[Si](C)(C)C(C)(C)C)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O[Si](C)(C)C(C)(C)C)[C@@H]21 | 3198.9 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol GC-MS (Non-derivatized) - 70eV, Positive | splash10-06tf-0192000000-febaf71cb7bb3ce7ddab | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol GC-MS (2 TMS) - 70eV, Positive | splash10-0002-2126900000-792439d40f989622f284 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 10V, Positive-QTOF | splash10-0uk9-0029000000-19a3ae7b670c2bbc4f91 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 20V, Positive-QTOF | splash10-0udr-0395000000-d86de9a9b8e51a4e333e | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 40V, Positive-QTOF | splash10-000f-2690000000-2828700e527e4071dd84 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 10V, Negative-QTOF | splash10-014i-0009000000-d7324ee3eff729ce20da | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 20V, Negative-QTOF | splash10-0gb9-0009000000-59443a42cdd02a1faa33 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 40V, Negative-QTOF | splash10-0ug0-1093000000-fc68bc0074752ab0a64d | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 10V, Positive-QTOF | splash10-0uk9-0129000000-ba68bf173da2e0146d03 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 20V, Positive-QTOF | splash10-0002-6923000000-bc7dd3eeba9b6e3b6163 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 40V, Positive-QTOF | splash10-0007-3900000000-7addaf6a3692944c1337 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 10V, Negative-QTOF | splash10-014i-0009000000-a90d3a3bae4a1d75273f | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 20V, Negative-QTOF | splash10-014i-0009000000-a90d3a3bae4a1d75273f | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 7a,17-dimethyl-5b-Androstane-3a,17b-diol 40V, Negative-QTOF | splash10-014i-0019000000-8c6fb945dd6e4541f7e4 | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
General References | - Saudan C, Baume N, Robinson N, Avois L, Mangin P, Saugy M: Testosterone and doping control. Br J Sports Med. 2006 Jul;40 Suppl 1:i21-4. [PubMed:16799097 ]
- Yesalis CE, Bahrke MS: Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):25-35. [PubMed:10932808 ]
- Furlanello F, Bentivegna S, Cappato R, De Ambroggi L: Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J. 2003 Dec;4(12):829-37. [PubMed:14976846 ]
- Bricout V, Wright F: Update on nandrolone and norsteroids: how endogenous or xenobiotic are these substances? Eur J Appl Physiol. 2004 Jun;92(1-2):1-12. Epub 2004 Mar 20. [PubMed:15042372 ]
- Foster ZJ, Housner JA: Anabolic-androgenic steroids and testosterone precursors: ergogenic aids and sport. Curr Sports Med Rep. 2004 Aug;3(4):234-41. [PubMed:15231229 ]
- Maughan RJ: Contamination of dietary supplements and positive drug tests in sport. J Sports Sci. 2005 Sep;23(9):883-9. [PubMed:16195040 ]
- Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, Karch SB: Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2007 Jan;121(1):48-53. Epub 2005 Nov 15. [PubMed:16292586 ]
- VanHelder WP, Kofman E, Tremblay MS: Anabolic steroids in sport. Can J Sport Sci. 1991 Dec;16(4):248-57. [PubMed:1663826 ]
- Thevis M, Schanzer W: Mass spectrometry in sports drug testing: Structure characterization and analytical assays. Mass Spectrom Rev. 2007 Jan-Feb;26(1):79-107. [PubMed:16888758 ]
- Green GA: Doping control for the team physician: a review of drug testing procedures in sport. Am J Sports Med. 2006 Oct;34(10):1690-8. Epub 2006 Aug 21. [PubMed:16923823 ]
- Furlanello F, Serdoz LV, Cappato R, De Ambroggi L: Illicit drugs and cardiac arrhythmias in athletes. Eur J Cardiovasc Prev Rehabil. 2007 Aug;14(4):487-94. [PubMed:17667636 ]
- Kerr JM, Congeni JA: Anabolic-androgenic steroids: use and abuse in pediatric patients. Pediatr Clin North Am. 2007 Aug;54(4):771-85, xii. [PubMed:17723876 ]
- Smurawa TM, Congeni JA: Testosterone precursors: use and abuse in pediatric athletes. Pediatr Clin North Am. 2007 Aug;54(4):787-96, xii. [PubMed:17723877 ]
- Yesalis CE, Anderson WA, Buckley WE, Wright JE: Incidence of the nonmedical use of anabolic-androgenic steroids. NIDA Res Monogr. 1990;102:97-112. [PubMed:2079979 ]
- Hatton CK, Catlin DH: Detection of androgenic anabolic steroids in urine. Clin Lab Med. 1987 Sep;7(3):655-68. [PubMed:3308301 ]
- Brower KJ: Anabolic steroids. Psychiatr Clin North Am. 1993 Mar;16(1):97-103. [PubMed:8456050 ]
- Schanzer W: Metabolism of anabolic androgenic steroids. Clin Chem. 1996 Jul;42(7):1001-20. [PubMed:8674183 ]
- Lukas SE: CNS effects and abuse liability of anabolic-androgenic steroids. Annu Rev Pharmacol Toxicol. 1996;36:333-57. [PubMed:8725393 ]
- Catlin DH, Hatton CK, Starcevic SH: Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Clin Chem. 1997 Jul;43(7):1280-8. [PubMed:9216475 ]
|
---|